Actively Recruiting
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Led by Peking University People's Hospital · Updated on 2025-04-29
38
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
Sponsors
P
Peking University People's Hospital
Lead Sponsor
B
Beihang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
CONDITIONS
Official Title
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with atypical endometrial hyperplasia or highly differentiated endometrioid adenocarcinoma stage IA without deep muscle infiltration, cervical involvement, or extrauterine metastasis
- Strong desire to preserve reproductive function
- Female patients aged 45 years or younger
- Patients predicted to be progesterone resistant by a sensitivity prediction model
- Provided informed consent
- Willing and able to attend follow-up visits
- Patients with normal or abnormal blood lipids who have not taken any lipid-lowering drugs
- Newly treated patients or those with persistent lesions after 12 weeks or partial remission after 24 weeks of prior treatment
You will not qualify if you...
- Severe internal diseases or significant liver and kidney impairment
- Disease progression or extrauterine metastasis during treatment
- Allergies or contraindications to therapeutic drugs
- Other types of endometrial cancer or malignant tumors of the reproductive system
- Breast cancer or other hormone-dependent tumors that prevent progesterone use
- History of deep vein thrombosis, stroke, or myocardial infarction during treatment
- Alcohol consumption over 20 grams per day
- Smoking more than 15 cigarettes per day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
J
Jianliu Wang, professor
CONTACT
H
HE YIJIAO, PHD/MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here